All In Biotech

Drug Trial Radar · NCT06441006

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Oct 3, 2025

Primary completion

Aug 2031

Study completion Aug 2031

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Johns Hopkins University
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PRISM-TB is an international, seamless, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, multi-arm multi-stage (MAMS), noninferiority Phase 2/3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB). In Stage 1, participants will be randomized among one of three treatment arms (one control and two experimental). Following the interim analysis (at the end of Stage 1) based on DOOR outcome comparisons and the entirety of the data, one of the four possible experimental strategies will be identified and continue into Stage 2. In Stage 2, participants will be randomized among one of two treatment arms (one control and one experimental). The trial objective is to identify, among participants with fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17 weeks for participants stratified to receive shorter treatment and 17 or 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, and to evaluate whether this BPaLM strategy has noninferior efficacy to the control strategy at Week 73.

Conditions

  • Tuberculosis, Pulmonary
  • Tuberculosis, Multidrug-Resistant
  • Tuberculosis, MDR

Interventions

  • BedaquilineDrug

    Frequency: daily Route of administration: oral

  • LinezolidDrug

    Frequency: daily Route of administration: oral

  • PretomanidDrug

    Frequency: daily Route of administration: oral

  • MoxifloxacinDrug

    Frequency: daily Route of administration: oral

  • Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelinesDrug

    The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 24 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest international guidelines and the local SOC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy Outcome: Desirability of Outcome Ranking (DOOR)Time frame: 73 weeks

Locations

6 sites in 5 countries. Site status is shown where the registry gives one.

  • National Center for Communicable Diseases

    Ulaanbaatar, Mongolia · Recruiting

  • Institute of Chest Diseases

    Kotri, Pakistan · Not yet recruiting

  • Hospital Nacional Sergio E. Bernales

    Lima, Peru · Recruiting

  • Policlínico SES

    Lima, Peru · Recruiting

  • Mulago National Referral Hospital

    Kampala, Uganda · Recruiting

  • Hanoi Lung Hospital

    Hanoi, Vietnam · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.